Jeremy Abramson, MD
Enriched profileProfessor of Medicine, Harvard Medical School; Director, Center for Lymphoma, Mass General Cancer Center · Massachusetts General Hospital
Jeremy Abramson is Professor of Medicine, Harvard Medical School; Director, Center for Lymphoma, Mass General Cancer Center at Massachusetts General Hospital. OpenAlex indexes 480 publications with 15,932 citations (h-index 65); ClinicalTrials.gov lists 16 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 15 Oct 2026
Jeremy Abramson, MD, is Professor of Medicine, Harvard Medical School at Massachusetts General Hospital / Mass General Cancer Center (Mass General Brigham). The public record shows 480 publications with 15,932 citations (h-index 65), centered on Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 24 companies.
- Most recent indexed publication: 2026 · Blood
- Top research focus: Lymphoma Diagnosis and Treatment
- 16 registered trials on ClinicalTrials.gov
- Open Payments reporting from 24 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 54 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 189.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:
- GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
Sponsor: Massachusetts General Hospital
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Sponsor: Allogene Therapeutics
- Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Sponsor: Cellectis S.A.
Industry payments
Updated 15 Oct 2026
24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Genentech, Inc.Program year202513 payments$25,751openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20252 payments$13,848openpaymentsdata.cms.gov ↗
- F. Hoffmann-La Roche AGProgram year20255 payments$10,029openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
41.3%Kinase inhibitor26.9%Brukinsa85%Jaypirca16%Part D<11 patientsBCL-2 Inhibitor14.4%Venclexta100%Part D<11 patientsMetabolism & gastrointestinal
26.1%Corticosteroid15.2%Prednisone100%Part D≥12 patientsSerotonin-3 Receptor Antagonist6.4%Ondansetron Hcl100%Part D≥12 patients+ 1 more class in this area
Anti-infectives
12.5%Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor8%Entecavir100%Part D<11 patientsShort-acting sulfonamides4.5%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 15 Oct 2026
101 congress contributions (2009–2025) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.
Journal of clinical oncology
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLArticle959 citations2018
- 02
- 03
- 04International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)Article381 citations2017
- 05
Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 15 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/scientific-contributions/Jeremy-S-Abramson-39400823
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
vjhemonc.com/speaker/jeremy-abramson
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗ - X / Twitter
twitter.com/LLSusa/status/1780342531198165435
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →twitter.com ↗ - X / Twitter
x.com/VJHemOnc/status/1782045626412531885
- X / Twitter
x.com/lymphomahub/status/1797921594616001001
- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗
- MD
Mount Sinai School of Medicine (New York City)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗ - MMSc (Master of Medical Sciences)
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗
Editorial & leadership roles
journal and society appointments- Panel Member
NCCN Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pubmed.ncbi.nlm.nih.gov ↗ - Fellow
American College of Physicians (FACP)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctor.webmd.com ↗ - Member
American Society of Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctor.webmd.com ↗ - Member
American Society of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctor.webmd.com ↗
Awards & honors
honors on the public record- Honoree
"The One Hundred" philanthropic recognition, Massachusetts General Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giving.massgeneral.org ↗
Media & interviews
press, podcasts and appearances- Recurring guest
Hematologic Oncology Update podcast, discussing CAR T-cell therapy and follicular lymphoma treatment strategies
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
- "Expert Point of View" commentary feature
The ASCO Post
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Wyndham Wilson, MD
National Cancer Institute (NCI)
Julie Vose, MD
University of Nebraska Medical Center